Eisai reveals new long-term seizure control data at ECE 2016
pharmafile | September 13, 2016 | News story | Manufacturing and Production, Research and Development | Eisai, epilepsy
Eisai has revealed new data on long-term seizure control in different seizure types at the 12th European Congress on Epileptology (ECE) 2016.
Among the findings, the company reported that an open-label extension study to a Phase III trial revealed clinical benefits and sustained seizure control in the use of once-daily adjunctive Fycompa (perampanel); 138 patients treated with the product for up to two and a half years observed a 93.1% reduction in median primary generalised tonic clonic (PGTC) seizure frequency.
Perampanel is indicated in the European Union for adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures, and for adjunctive treatment of PGTC seizures in patients with IGE aged 12 years and older.
Additionally, the company reported that 26.8% of patients with Lennox-Gastaut Syndrome (LGS) treated with Inovelon (rufinamide) were “much” or “very much” improved in seizure control at 12 months, compared with 15.2% for other anti-epileptic drugs (AEDs). After 24 months, the proportion of patients reporting the same for control of all seizures was 28.6%, but with other AEDs this had risen to 50%.
“The data presented for perampanel and rufinamide provide new insights into the long-term care of people with epilepsy,” explained Neil West, vice president, Global Neurology Business Group at Eisai EMEA. “There is no known cure and people have to live with the consequence of epilepsy day in and day out. Eisai is committed to understanding the long-term impact of its treatments, for seizure freedom and safety, and these results help us to enhance our knowledge of treatment in everyday life.”
Matt Fellows
Related Content
EpilepsyGTx raises $33m for focal refractory epilepsy gene therapy
EpilepsyGTx, a biotechnology company researching and developing gene therapies for the treatment of refractory epilepsy, …
UCB presents positive results for fenfluramine in CDKL5 deficiency disorder
UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can …
Rare and severe epilepsies – current treatments and advance therapeutics
The current forms of immunotherapy, how T cell therapy works and what the future holds
